Zuellig Pharma, a leading healthcare solutions company in Asia, announced the strategic acquisition of a specialized clinical supply facility in Hangzhou, China, strengthening its clinical sourcing capabilities to better support domestic and international clinical trials.
The Hangzhou facility holds a Drug Distribution License (DDL), enabling Zuellig Pharma to provide local clinical sourcing of comparator drugs and concomitant medications in China. This strengthens Zuellig Pharma's ability to offer compliant, in-market sourcing solutions while streamlining billing processes and creating opportunities for value-added tax (VAT) savings for clinical trial sponsors.
"Asia is playing an increasingly important role in global clinical research and drug development, and China is a critical market within this ecosystem. This strategic acquisition reflects our continued commitment to investing in the infrastructure and capabilities needed to support the regional and global healthcare needs. By strengthening our clinical trial support network, we are helping our partners accelerate the development of innovative therapies for patients across Asia and beyond," said John Graham, Group Chief Executive Officer, Zuellig Pharma.
"Our focus remains on removing logistical hurdles to clinical development, ensuring critical supplies reach trial sites and patients safely. The addition of our licensed Hangzhou facility represents a significant step forward in strengthening our clinical trial supply capabilities in China. By bringing local sourcing, and distribution capabilities together, we are enabling our life science partners to conduct both domestic studies and multi-regional clinical trials (MRCTs) with faster cycle times, uncompromised regulatory compliance, and robust cold-chain integrity," said David Christmas, Executive Vice President of Distribution & Clinical Trial Support.